Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-07-09 EDT			5-day change	1st Jan Change
443.05 ^DKK	-1.53%		+1.07%	-29.02%

07-09	Major deals involving U.S. drugmakers and biotechs over the past decade	RE
07-09	European shares close at four-week high on banks boost; US trade talks in focus	RE

Novo Nordisk Says Planning To Initiate A Phase 3 Development Programme With Amycretin For Adults With Overweight Or Obesity During Q1 Of 2026

Published on 2025-06-12 at 13:12

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
European shares close at four-week high on banks boost; US trade talks in focus	07-09	RE
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update	07-09	DJ
NOVO NORDISK : Deutsche Bank remains its Buy rating	07-09	ZD
Europe rises despite new US tariff mayhem	07-09	AN
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
European shares rise on energy, healthcare boost; tariff uncertainty lingers	07-08	RE
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	07-08	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	07-08	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	07-08	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	07-08	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	07-08	FW
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	07-08	MT
Novo Nordisk submits new Wegovy dose to the European Medicines Agency for approval	07-08	RE
Novo Nordisk submits application to EMA for approval of higher dose of Wegovy	07-08	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	07-08	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07-07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07-07	RE
The importance of being constantly changing…	07-07
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07-07	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07-07	RE
European shares fall as banks, mining stocks losses weigh	07-04	RE
Jyske Bank Lowers Novo Nordisk Price Target to 700 Danish Kroner, Reiterates Buy - BN	07-04	FW
SAP Becomes Europe's Most Valuable Company as Nvidia Leads Globally	07-03	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

08-06 - Q2 2025 Earnings Release

More about the company